mRNA LIGHTNING PLATFORM
DISCOVERY OF SMALL MOLECULE mRNA DRUGS
HIGH SCALE
PHENOTYPIC SCREENING
AUTOMATED BIOLOGY LAB
MILLIONS OF
mRNA TRANSLATION IMAGES
ANALYZED WITH AI TECHNOLOGY
ELUCIDATING THE
MECHANISM OF ACTION
PIPELINE OF 18 PROGRAMS
BIG PHARMA PARTNERSHIPS

Anima Biotech mRNA Lightning Platform

We are advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale automated phenotypic screening in live biology with AI mRNA image analysis that elucidates the mechanism of action of active compounds. We develop our own pipeline and partner with pharma on additional targets.

Pharma Collaborations

Anima Biotech announces a strategic collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

Anima Biotech announces strategic collaboration with Takeda to discover and develop mRNA translation modulators for Neurological diseases »

Up to $120 million in upfront and preclinical research milestone payments, up to $1.1 billion in clinical and commercial milestones and tiered royalties on sales of any Takeda products resulting from the collaboration. Takeda has a time limited option to expand the collaboration subject to additional payments to Anima of up to $1.2 billion and tiered royalties.

Anima Biotech achieves first milestone in Takeda collaboration »

The milestone relates to the Huntington’s Disease program which is part of a multi-target research collaboration between the companies. This achievement entitles Anima to an undisclosed milestone payment.

Anima Biotech achieves milestone in Takeda collaboration »

The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.

For partnering inquiries, please contact [email protected].

mRNA Lightning Platform

Automated high scale phenotypic screening combining live biology with AI mRNA image analysis for the discovery of small molecule mRNA drugs and their mechanisms of action.

Cloud based AI mRNA Image analysis
Brightny
Compass
Cerebio
TranslationLight
mRNA translation images
High content imaging
High scale automated screening
Plate tower
Robot
Compound library
mRNA Biology automated screening lab
Cerebio Bioinformatics algorithms that select signature tRNA pair for an mRNA of interest
TranslationLight High content screening for mRNA translation modulators
Brightny Cloud-based big data AI mRNA image analysis identifies active and selective molecules
Compass Mechanism of action and Target identification
Cloud Cloud-based big data AI mRNA image analysis identifies active and selective molecules along with their mechanism of action and molecular targets.
mRNA Translation images 50 million mRNA translation images are uploaded to the cloud server for analysis
High content imaging 50 million mRNA translation images are uploaded to the cloud server for analysis
High scale automated screening Fully automated screen running 24/7 for 3 weeks
Plate Tower +200,000 diverse drug-like small molecules
Robot Fully automated screen running 24/7 for 3 weeks
Compound library +200,000 diverse drug-like small molecules
Watch Movie: mRNA Lightning Platform
Watch Movie: mRNA translation control

A novel approach for the discovery of small molecule mRNA drugs that selectively control mRNA biology as a new strategy against hard targets and undruggable proteins.

Watch Movie: Identification of active and selective mRNA translation modulators

Our platform is using fluorescently labeled tRNA pairs to generate FRET signals, light pulses emitted from the ribosomes to visualize the translation of any mRNA of interest and identify selective translation modulators.

See the Light of mRNA Translation

The Selectivity of mRNA Translation Biology

Cells control mRNA translation using multiple selective mechanisms, offering novel intervention points. Modulation of mRNA biology is therefore possible with highly selective drugs.

Tissue
Tissue specific regulation
Cells
Normal vs. cancer cells
Pathway
Up or down regulated in pathological pathway
mRNA
Sequence and structure

mRNA translation modulators
A novel target space

mRNA
Biology
Ribosome accessory proteins
Epitranscriptomics (mRNA modifying proteins)
Splicing factors
Modifiers of ribosomal proteins (Kinases, methylases etc...)
tRNA abundance and control
RNA binding proteins

Small molecule drugs targeting novel proteins involved in the regulation of mRNA translation

mRNA Translation Modulators Pipeline

Our high scale screening platform identifies compounds that modulate mRNA biology. Our mRNA AI image analysis then rapidly elucidates their mechanism of action.

With this unique approach we were able to develop a broad pipeline of small molecule mRNA drugs, advancing 18 discovery programs across therapeutic areas at unparalleled speed and success rate.

Anima wholly owned pipeline programs are in Fibrosis (tissue selective Collagen I translation inhibitors, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc translation inhibitors and mutation agnostic mKras translation inhibitors), and Neuroscience (Tau - Alzheimer’s disease and Pain - Nav1.7 translation inhibitors) with additional programs in Repeat Associated Diseases. In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our large scale collaborations with Lilly and Takeda Pharmaceuticals.

Indication Target
Discovery
Optimization
IND enabling
Anima owned
Fibrosis
Lung Fibrosis 1
Collagen-1 2
3
Other Fibrotic 4
Oncology
c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Neuroscience
Alzheimer TAU 9
10
Repeat diseases Undisclosed 11
Pain Nav 1.7 12
Undisclosed 13
Partnered
Huntington mHTT 14
Undisclosed takeda logo lilly logo 15
Undisclosed 16
Undisclosed 17
Undisclosed 18
Anima owned
Partnered
Area Indication mRNA modulation Target
Discovery
Optimization
IND enabling
Fibrosis Lung Fibrosis 1
Collagen-1 2
3
Other Fibrotic 4
Oncology c-Myc tumors c-Myc 5
6
7
mKRAS tumors mKRAS 8
Neuroscience Alzheimer TAU 9
10
Repeat diseases Undisclosed 11
Pain Nav 1.7 12
Undisclosed 13
Undisclosed takeda logo lilly logo 14
Huntington mHTT 15
Undisclosed 16
Undisclosed 17
Undisclosed 18

17 Scientific Collaborations

15 Peer Reviewed Publications

Coverage

News & Events

  • Anima Biotech achieves milestone in Takeda collaboration

    When: Jul. 20th, 2022

    Anima Biotech announced that the company has achieved a milestone in its collaboration with Takeda. 

    The milestone relates to one of the two newly initiated programs as part of the multi-target collaboration. This achievement entitles Anima to an undisclosed milestone payment.

    Download Press Release »

  • Oxford Global Discovery Europe

    When: Jun. 9th, 2022 - Jun. 10th, 2022
    Where: Berlin, Germany

    Anima Biotech has been invited to participate in the Oxford Global Discovery Europe Summit.
    Our Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D., will participate in a panel discussion titled, “Targeting The RNA As a Modality,” on June 9, 2022, at 2:10 p.m. CEST.

    Visit the conference website »

  • Cambridge Healthtech Institute’s 3rd Annual RNA-Targeting Small Molecule Drugs

    When: Apr. 20th, 2022 - Apr. 21st, 2022
    Where: San Diego, CA & online

    Anima Biotech’s Co-Founder and Chief Scientific Officer, Iris Alroy, Ph.D.

    Visit conference website »